Armata Pharmaceuticals Inc (ARMP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Armata Pharmaceuticals Inc stock (ARMP) is currently trading at $8.21. Armata Pharmaceuticals Inc PS ratio (Price-to-Sales) is 60.44. Analyst consensus price target for ARMP is $15.00. WallStSmart rates ARMP as Sell.
- ARMP PE ratio analysis and historical PE chart
- ARMP PS ratio (Price-to-Sales) history and trend
- ARMP intrinsic value — DCF, Graham Number, EPV models
- ARMP stock price prediction 2025 2026 2027 2028 2029 2030
- ARMP fair value vs current price
- ARMP insider transactions and insider buying
- Is ARMP undervalued or overvalued?
- Armata Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ARMP Piotroski F-Score and Altman Z-Score
- ARMP analyst price target and Smart Rating
Armata Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Armata Pharmaceuticals Inc (ARMP) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Armata Pharmaceuticals Inc (ARMP) Key Strengths (0)
Supporting Valuation Data
Armata Pharmaceuticals Inc (ARMP) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -61.00%, a shrinking business
Very expensive at 60.4x annual revenue
Very low institutional interest at 3.41%
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Armata Pharmaceuticals Inc (ARMP) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (60.44), Price/Book (2.11) suggest expensive pricing. Growth concerns include Revenue Growth at -61.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -3439.00%, Operating Margin at -671.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3439.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -61.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARMP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARMP's Price-to-Sales ratio of 60.44x trades at a deep discount to its historical average of 374.73x (53th percentile). The current valuation is 99% below its historical high of 4932.55x set in Jun 2020, and 25083% above its historical low of 0.24x in Oct 2011. Over the past 12 months, the PS ratio has expanded from ~11.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Armata Pharmaceuticals Inc (ARMP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Armata Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 5M with 61% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 115% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 61% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Armata Pharmaceuticals Inc.
Bottom Line
Armata Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Armata Pharmaceuticals Inc(ARMP)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.